Compare i-80 Gold Corp. Common Shares (IAUX) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
i-80 Gold Corp. Common Shares vs Neurocrine Biosciences Inc — how do they compare? i-80 Gold Corp. Common Shares trades at $1.49 (market cap $1.26B), while Neurocrine Biosciences Inc trades at $136.25 (market cap $13.82B). The key difference: Neurocrine Biosciences Inc is far larger — about 11× i-80 Gold Corp. Common Shares's market cap, and i-80 Gold Corp. Common Shares is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold i-80 Gold Corp. Common Shares for 0 Days and Neurocrine Biosciences Inc for 24 Days on average.
| IAUX | NBIX | |
|---|---|---|
Market Cap | $1.26B | $13.82B |
Volume | 10,665,602 | 1,506,669 |
Sector | Basic Materials | Health |
52-Week High | $2.08 | $185.50 |
52-Week Low | $0.89 | $123.10 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $1.24B | $13.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAUX trades at $1.54, down 2.53% today, with a neutral technical signal. The company shows significant financial challenges with a -198.82% net income margin and negative ROE of -71.66%, though revenue grew from $95M in 2025 to $130M in 2026. Recent positive developments include CEO purchasing 1 million shares and feasibility studies showing strong potential for Nevada gold projects. Analyst consensus remains unanimously bullish with 3 buy ratings.
While facing substantial profitability challenges, IAUX's development pipeline and CEO confidence suggest long-term potential. Key risks include persistent negative cash flow from operations and high debt levels. The stock presents a high-risk, high-reward opportunity dependent on successful project execution and gold price stability.
Neurocrine Biosciences (NBIX) trades at $135.13, down 4.41% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 19.87 and robust profitability, including a net income margin of 20.91% and three consecutive quarterly earnings beats. Recent news highlights pipeline progress and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive given strong earnings momentum and product growth, but risks include execution challenges and pricing pressures. The current price offers a significant discount to the analyst target, presenting a potential opportunity for investors comfortable with the biopharmaceutical sector's inherent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About i-80 Gold Corp. Common Shares
i-80 Gold Corp. is a mining company focused on developing and operating gold and precious-metals projects in Nevada, using a hub-and-spoke model centered on a processing facility to support multiple mine sites in the state.
Read more on IAUX →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
